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Disability Index. Data at screening and baseline were used to
examine the convergent validity, discriminant validity, internal
consistency, and test-retest reliability. Convergent validity was
tested, using Pearson’s correlations, by comparing total and sub-
scale scores on the CSHQ-RA to those from the Mental and
Physical Component Summary (MCS and PCS) of the MOS SF-
36 and HAQ. ANOVA and Kruskal-Wallis tests were used to
assess the discriminant validity of the CSHQ-RA. Internal 
consistency was measured by Cronbach’s alpha coefﬁcient.
Test–retest reliability was assessed using intraclass correlation
coefﬁcients (ICCs). RESULTS: Response rate at baseline was
95% (291). Eighty-one percent of respondents were female;
mean age was 52 years (± 12); mean duration with RA was 10.8
years (± 10.4). At baseline, mean scores on instruments were
HAQ 1.5 (± 0.7), MCS 37.9 (± 10.9), and PCS 31.2 (± 8.3).
Pearson’s correlations between the CSHQ-RA and the MOS SF-
36 and HAQ scores ranged from -0.33 to -0.73 (P < 0.0001)
and 0.39 to 0.76 (P < 0.0001), respectively. The difference in
scores on the CSHQ-RA of patients with different levels of phys-
ical disability as measured by the HAQ was statistically signiﬁ-
cant (P < 0.0001). Cronbach’s alpha coefﬁcients were ≥0.9
indicating good internal consistency. Test-retest reliability was
demonstrated in the instrument’s subscales with ICCs ranging
from 0.82 to 0.94. CONCLUSIONS: These results support the
validity and reliability of the original CSHQ-RA when tested in
a representative patient population. Research to assess respon-
siveness and clinically signiﬁcant change of the CSHQ-RA is
underway.
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THE DEVELOPMENT OF PROPENSITY SCORES FROM
ADMINISTRATIVE DATABASES FOR THE ANALYSIS OF THE
EFFECTIVENESS OF AN OSTEOARTHRITIS ACADEMIC
DETAILING SERVICE ON PRESCRIBING BEHAVIOUR
Graham SD, Hartzema AG
University of Florida, Gainesville, FL, USA
OBJECTIVES: The Nova Scotia Osteoarthritis (OA) Academic
Detailing Service is voluntary and as such questions of selection
bias when comparing the physicians’ prescribing behaviour that
volunteered with those that did not are justiﬁed. The objective
is to abate this bias, using propensity score methodology to
create balanced experimental groups for the analysis of pre-
scribing behaviour. METHODS: A total of 989 of the 1403
general practicioners in Nova Scotia met the inclusion criteria
for the study (312 received the OA service, 677 did not). The
propensity score for each physician was calculated using a logis-
tic regression analysis; with participation in the OA service as
the dependent variable and 10 independent variables that
described the physician’s personal and practice characteristics.
RESULTS: The 10 independent variables were tested for signif-
icant differences (alpha = 0.05, t-test for continuous and chi-sq
for catagorical variables) before and after the propensity analy-
sis was conducted. Nine of the 10 variables showed signiﬁcant
difference between the experimental groups in the pre-
propensity comparison whereas only 1 variable showed a sig-
niﬁcant difference in the post-propensity comparison. CON-
CLUSIONS: The propensity score methodology was successful
in abating selection bias by eliminating signiﬁcant differences
between variables measuring physician characteristics. It also
identiﬁed one variable (participation in a previous inﬂuenza
detailing service), which remained a signiﬁcant predictor of 
participation in the OA service after the propensity score was
completed (pre-propensity chisq = 407.48, p < 0.0001 and 
post-propensity chisq = 15.46, p < 0.0001). As such, there is a
strong argument that this variable should be included as a covari-
ate in the statistical analysis of behavioural differences between
the groups.
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OBJECTIVES: Prescription drugs that provide high value should
command higher prices than lower value drugs other things
equal. We examined correlations between a drug’s price and its
economic merit, as measured in cost-utility analysis (CUAs). We
also examined whether formularies policies are consistent with
cost-utility (CU) ratios. METHODS: CUAs from 1998 through
2001 on pharmacotherapies were selected from a large registry
of analyses. All CU ratios and drug cost estimates were taken as
reported in analyses and standardized to 2002 US$. Spearman
correlation coefﬁcients were used to quantify the association
between drug prices and CU ratios. We examined the Florida
Medicaid Preferred Drug List and Harvard Pilgrim Pharmacy
Program to analyze whether insurers cover drugs with good
value. Wilcoxon rank sum test was performed to assess if pre-
ferred drugs had different ratios than non-preferred drugs.
RESULTS: Of 205 ratios, 16.1% were for short-term treatment
(<2 months), 29.8% intermediate treatment (2–18 months), and
54.2% lifetime treatment. Ten and seven-tenths percent of ratios
were cost saving and 8.3% dominated. Correlations between
ratios and prices were 0.4991 (p = 0.0069), 0.1154 (p = 0.4724)
and 0.2892 (p = 0.0041) for short, intermediate, and lifelong
drugs, respectively. CU ratios did not differ signiﬁcantly from
preferred to non-preferred drugs on both health plans. Among
cost-saving therapies, only 68.2% were covered by Florida Med-
icaid and 72.7% by Harvard Pilgrim. Among dominated drug
interventions, 88.2% were covered by Florida Medicaid and
94.12% by Harvard Pilgrim. CONCLUSIONS: CU ratios of
pharmacotherapies are positively associated with price, but the
correlation is low among intermediate and lifelong treatments.
Preferred drugs on two health plans generally do not reﬂect
better cost-effectiveness. These results may reﬂect the absence of
value-based pricing and lack of evidence-based reimbursement
policies, or the fact that CUAs are poorly conducted (e.g., they
have inappropriate comparators), or do not reﬂect decision
makers’ perceptions of value.
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DECISION-MAKER’S PERCEPTIONS OF ACCESS TO HIGH
COST DRUGS (HCDS) IN PUBLIC HOSPITALS IN AUSTRALIA
Gallego G,Taylor S, Brien JAE
The University of Sydney, Sydney, NSW, Australia
OBJECTIVE: To investigate the perceptions, concerns and atti-
tudes of decision-makers regarding access to HCDs in public
hospitals. METHODS: In-depth, semi-structured interviews
were conducted with public hospital senior managers, directors
of pharmacy and senior medical doctors in a Sydney Area Health
Service. Topics for the interviews included the decision-making
process and associated problems and solutions to matters of
access to HCDs. Interviews were audiotaped, transcribed verba-
tim, thematically content analyzed and coded using NVivo soft-
ware. RESULTS: Data analysis identiﬁed a number of emerging
themes. Decision-makers perceived health care system funding
